Esperion Therapeutics Inc (NASDAQ: ESPR) started the day on N/A, with a price increase of 1.38% at $2.21, before settling in for the price of $2.18 at the close. Taking a more long-term approach, ESPR posted a 52-week range of $0.69-$3.94.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 40.11% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 40.11%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 68.75%. This publicly-traded company’s shares outstanding now amounts to $200.16 million, simultaneously with a float of $196.97 million. The organization now has a market capitalization sitting at $445.59 million. At the time of writing, stock’s 50-day Moving Average stood at $1.50, while the 200-day Moving Average is $1.66.
Esperion Therapeutics Inc (ESPR) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Esperion Therapeutics Inc’s current insider ownership accounts for 2.31%, in contrast to 48.89% institutional ownership. According to the most recent insider trade that took place on Jul 17 ’25, this organization’s General Counsel sold 1,304 shares at the rate of 1.13, making the entire transaction reach 1,470 in total value, affecting insider ownership by 399,937. Preceding that transaction, on Jul 17 ’25, Company’s Chief Financial Officer sold 11 for 1.11, making the whole transaction’s value amount to 12. This particular insider is now the holder of 474,462 in total.
Esperion Therapeutics Inc (ESPR) Earnings and Revenue Records
Esperion Therapeutics Inc (NASDAQ: ESPR) Trading Performance Indicators
Let’s observe the current performance indicators for Esperion Therapeutics Inc (ESPR). It’s Quick Ratio in the last reported quarter now stands at 0.76. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.66.
In the same vein, ESPR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.53, a figure that is expected to reach 0.02 in the next quarter, and analysts are predicting that it will be -0.01 at the market close of one year from today.
Technical Analysis of Esperion Therapeutics Inc (ESPR)
If we take a close look at the recent performances of Esperion Therapeutics Inc (NASDAQ: ESPR), its last 5-days Average volume was 4.35 million that shows plunge from its year to date volume of 4.8 million. During the previous 9 days, stock’s Stochastic %D was recorded 70.41% While, its Average True Range was 75.07%.
Raw Stochastic average of Esperion Therapeutics Inc (ESPR) in the period of the previous 100 days is set at 94.99%, which indicates a major rise in contrast to 85.45% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.12 that was higher than 0.11 volatility it exhibited in the past 100-days period.
